Serina Therapeutics has entered into definitive agreements for a private placement that could provide up to $30 million to support the advancement of its clinical trial evaluating SER-252 (POZ-apomorphine) as a treatment for people with advanced Parkinson’s disease. The global Phase 1b trial (NCT07422675) is evaluating the…
